Skip to main content

Table 1 Demographic and clinical characteristics of participants

From: Circulating amino acids and acylcarnitines correlated with different CAC score ranges in diabetic postmenopausal women using LC–MS/MS based metabolomics approach

 

Controls

Diabetes without CVD

Diabetes + Low-risk CVD

Diabetes + High-risk CVD

P-value

N (%)

20 (29.4%)

16 (23.5%)

11 (16.2%)

21 (30.9%)

 

Age (year)

62.55 ± 5.708

62.06 ± 6.082

64.55 ± 5.681

66.62 ± 8.255

0.145*

Years of menopause

15.4 ± 7.148

15.94 ± 9.943

15.36 ± 7.406

19.33 ± 11.702

0.513*

Duration of diabetes (year)

0

6.87 ± 3.55

16 ± 8.56

11.6 ± 7.76

 ≤ 0.001*

BMI (kg/m2)

30.37 ± 4.9529

29.075 ± 4.1130

28.227 ± 4.3941

31.671 ± 6.7291

0.291*

Biochemistry tests

  Uric Acid (mg/dL)

4.895 ± 1.3763

5.406 ± 1.5181

4.873 ± 1.4065

5.176 ± 1.0392

0.632*

  Creatinine (mg/dL)

0.76 (0.69–0.87)

0.86 (0.75–0.93)

0.87 (0.73–1.01)

0.81 (0.71–0.88)

0.438**

  GFR (mL/min/1.73m2)

93.5 (90–97.5)

87.5 (76–97.5)

84 (71–98)

87 (80–95)

0.516**

  HbA1c (%)

6.04 (5.76–6.88)

5.74 (5.63–6.45)

6.51 (5.83–7.31)

5.72 (5.44–6.1)

0.076**

  Cholesterol (mg/dL)

158.4 ± 36.151

157.19 ± 25.002

165.73 ± 22.258

179.48 ± 35.785

0.116*

  HDL-C (mg/dL)

43.8 ± 11.669

41.06 ± 6.382

49 ± 16.131

39.95 ± 7.486

0.117*

  LDL-C (mg/dL)

70.2 ± 31.388

76.25 ± 26.07

68.36 ± 18.101

91.71 ± 29.16

0.053*

  AST (U/L)

18 (16–23.5)

20 (17–21.5)

20 (18–21)

19 (15–23)

0.757**

  ALT (U/L)

10.5 (8–15.5)

8.5 (7–14.5)

12 (6–17)

10 (7–13)

0.563**

Medications

  Aspirin

9 (45%)

7 (43.8%)

5 (45.5%)

13 (61.9%)

0.63

  Anticonvulsant

0

0

2 (18.2%)

1 (4.8%)

0.085

  Diuretics

1 (5%)

1 (6.3%)

3 (27.3%)

6 (28.6%)

0.094

  B-blockers

5 (25%)

5 (31.3%)

9 (81.8%)

15 (71.4%)

0.001

  ACEi

1 (5%)

1 (6.3%)

0

3 (14.3%)

0.467

  ARB

8 (40%)

9 (56.3%)

7 (63.6%)

13 (61.9%)

0.466

  CCB

3 (15%)

0

2 (18.2%)

5 (23.8%)

0.235

  Metformin

0

13 (81.3%)

10 (90.9%)

20 (95.2%)

 < 0.001

  Insulin

0

3 (18.8%)

2 (18.2%)

6 (28.6%)

0.096

  Statins

11 (55%)

10 (62.5%)

6 (54.5%)

19 (90.5%)

0.057

  Anticoagulant

2 (10%)

0

0

5 (23.8%)

0.064

  Nitroglycerine

8 (40%)

1 (6.3%)

1 (9.1%)

14 (66.7%)

 < 0.001

  1. BMI Body mass index, GFR Glomerular filtration rate, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ACEi Angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blockers, CCB Calcium channel blockers
  2. Data are represented as n (%), means ± standard deviation, median (interquartile range(Q1-Q3))
  3. *P-values for comparisons between groups derived by ANOVA test
  4. **P-values for comparisons between groups derived by Kruskal–Wallis’s test
  5. P-values for comparisons between groups of medications derived by Pearson Chi-Square test
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us